Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals Inc (CRNX) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's mission is to improve the lives of patients by advancing innovative treatments that address unmet medical needs. Crinetics Pharmaceuticals Inc (CRNX) generates revenue primarily through the sale of its products and the licensing of its intellectual property.

The income statement provides a snapshot of the company's financial performance over a specific period. It includes information on revenue, expenses, and net income. For Crinetics Pharmaceuticals Inc (CRNX), the income statement shows that the total revenue for the most recent period was $X.XX million. The gross profit, which is the revenue minus the cost of goods sold, was $X.XX million. The operating expenses, such as research and development costs, sales and marketing expenses, and general and administrative expenses, totaled $X.XX million. The EBIT, or earnings before interest and taxes, was $X.XX million, and the EBITDA, or earnings before interest, taxes, depreciation, and amortization, was $X.XX million. The net income from stockholders, which represents the profit attributable to the company's owners, was $X.XX million.

The balance sheet provides information on the company's assets, liabilities, and stockholders' equity at a specific point in time. For Crinetics Pharmaceuticals Inc (CRNX), the total assets were $X.XX million, including cash and cash equivalents of $X.XX million. The total liabilities, which include short-term and long-term debts, were $X.XX million. The stockholders' equity, which represents the owners' stake in the company, was $X.XX million. The net debt, which is the company's total debt minus its cash and cash equivalents, was $X.XX million.

The cash flow statement provides information on the company's sources and uses of cash during a specific period. It includes operating cash flow, investing cash flow, and financing cash flow. For Crinetics Pharmaceuticals Inc (CRNX), the operating cash flow, which represents the cash generated from the company's core business operations, was $X.XX million. The investing cash flow, which includes cash spent on acquisitions, investments, and capital expenditures, was $X.XX million. The financing cash flow, which includes cash spent on debt repayments and stock repurchases or cash raised from debt issuances and stock sales, was $X.XX million. The free cash flow, which represents the cash available for distribution to stockholders after deducting capital expenditures, was $X.XX million.